alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Drug trials: efficacy and safety

902 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neuropharmacology 2020-10-06 Treatments

    Alzheimer's disease (AD), the most common cause of adult-onset dementia is characterized by a progressive decline of cognitive functions accompanied by behavioral manifestations.

  2. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. American Journal of Psychiatry 2016-05-01 Clinical safety

    Author(s): Reus, Victor I; Fochtmann, Laura J; Eyler, A Evan; Hilty, Donald M; Horvitz-Lennon, Marcela; Jibson, Michael D; Lopez, Oscar L; Mahoney, Jane; Pasic, Jagoda; Tan, Zaldy S; Wills, Cheryl D; Rhoads, Richard; Yager, Joel

  3. One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in neuroscience 2016-04-25 Drug development

    HIGHLIGHTS Many AD target combinations are being explored for multi-target drug design.

  4. Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Current medicinal chemistry 2015-01-01 Treatments

    Alzheimer's disease (AD) is a complex and progressive neurodegenerative disorder.

  5. Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer's research & therapy 2014-03-24 Treatments

    The symptomatic drugs currently on the market for Alzheimer's disease (AD) have no effect on disease progression, and this creates a large unmet medical need.

  6. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-07-01 Treatments

    An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on October 31, 2012, to review lessons learned from the recent bapineuzumab and solanezumab trials, and to incorporate insights gained from these trials into future clinical studies.

  7. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurotoxicity research 2013-05-09 Treatments

    This review describes the preclinical mechanisms that may underlie the increased therapeutic benefit of combination therapy-with the N-methyl-D-aspartate receptor antagonist, memantine, and an acetylcholinesterase inhibitor (AChEI)-for the treatment of Alzheimer's disease (AD).

  8. Acetylcholinesterase inhibitors: pharmacology and toxicology

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Current neuropharmacology 2013-05-01 Treatments

    Acetylcholinesterase is involved in the termination of impulse transmission by rapid hydrolysis of the neurotransmitter acetylcholine in numerous cholinergic pathways in the central and peripheral nervous systems.

  9. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2012-04-27 Treatments

    The rivastigmine (RHT) loaded chitosan nanoparticles (CS-RHT NPs) were prepared by ionic gelation method to improve the bioavailability and enhance the uptake of RHT to the brain via intranasal (i.n.) delivery.

  10. New acetylcholinesterase inhibitors for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. International journal of Alzheimer's disease 2011-12-15 Treatments

    Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD.

  11. The heterogeneity of “major depression”

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. World Psychiatry 2011-10-01 Risk factors

    They concluded that their results “challenge our understanding of major depression as a homogeneous categorical entity”.

  12. Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard Ellman's method

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. International journal of molecular sciences 2011-04-18 Risk factors

    Assay of acetylcholinesterase (AChE) activity plays an important role in diagnostic, detection of pesticides and nerve agents, in vitro characterization of toxins and drugs including potential treatments for Alzheimer's disease.

  13. Drugs for Alzheimer's disease: are they effective?

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. PubMed Central 2010-04-01 End-of-life care

    Alzheimer’s disease (AD), a devastating neurodegenerative disorder, is the leading cause of dementia in the U.S. and in other developed countries.

  14. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2008-08-01 Digital health tools

    Although the warnings slowed the growth in the use of atypical antipsychotic drugs among patients with dementia, they did not reduce the overall prescription rate of these potentially dangerous drugs.

  15. Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer Disease & Associated Disorders 2008-07-01 Treatments

    Covarying for baseline scores, age, education, and duration of illness, the COMBO group had significantly lower mean annualized rates of deterioration in BDS and ADL scores compared with the CI (P<0.001; Cohen's dBDS=0.10-0.34 and dADL=0.23-0.46 at 1 to 2 y) and NO-RX groups (P<0.001; Cohen's dBDS=0.56-0.73 and dADL=0.32-0.48 at 1 to 2 y).

  16. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Annals of internal medicine 2008-03-01 Treatments

    Description The American College of Physicians and American Academy of Family Physicians developed this guideline to present the available evidence on current pharmacologic treatment of dementia.

  17. Six-Month Randomized, Placebo-Controlled, Double-Blind, Pilot Clinical Trial of Curcumin in Patients With Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Clinical Psychopharmacology 2008-02-01 Clinical trials

    Baum, Larry PhD; Lam, Christopher Wai Kei PhD; Cheung, Stanley Kwok-Kuen MSc; Kwok, Timothy MD; Lui, Victor MRCPsych; Tsoh, Joshua MRCPsych; Lam, Linda MD, MRCPsych; Leung, Vivian FHKCPsy; Hui, Elsie FRCP; Ng, Chelsia HBSc; Woo, Jean MD; Chiu, Helen Fung Kum FRCPsych; Goggins, William B. ScD; Zee, Benny Chung-Ying PhD; Cheng, King Fai MD; Fong, Carmen Yuet Shim RN; Wong, Adrian BSc; Mok, Hazel BSc; Chow, Moses Sing Sum PharmD; Ho, Ping Chuen PhD; Ip, Siu Po PhD; Ho, Chung Shun PhD; Yu, Xiong Wen PhD; Lai, Caroline Yau Lin MMedSc; Chan, Ming-Houng FHKCPhys; Szeto, Samuel FRCP; Chan, Iris Hiu Shuen PhD; Mok, Vincent MD Author Information

  18. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet. Neurology 2006-11-01 Treatments

    Parkinson's disease is classically characterised as a motor neurodegenerative disorder.

  19. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurology 2006-07-10 Treatments

    Patients treated with memantine had significantly lower NPI total scores than patients treated with placebo.

  20. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Neurology 2006-04-01 Treatments

    Screening tools are available for depression and dementia in patients with PD, but more specific validated tools are needed.

  21. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neurology, neurosurgery, and psychiatry 2005-12-01 Clinical safety

    Despite moderate motor and cognitive decline, probably due to disease progression, the marked improvement in motor function observed postoperatively was sustained 5 years after neurosurgery.

  22. Glutamate as a therapeutic target in psychiatric disorders

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Molecular psychiatry 2004-11-01 Clinical trials

    Glutamate is the primary excitatory neurotransmitter in the mammalian brain.

  23. Treatment of Alzheimer's disease: current status and new perspectives

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet. Neurology 2003-09-01 Treatments

    Alzheimer's disease (AD) is the most common neurodegenerative disorder and the most prevalent cause of dementia with ageing.

  24. Alzheimer's disease: treatments in discovery and development

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Nature neuroscience 2002-11-01 Treatments

    Alzheimer's disease is the single biggest unmet medical need in neurology.

  25. Research and Development of Donepezil Hydrochloride, a New Type of Acetylcholinesterase Inhibitor

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Japanese Journal of Pharmacology 2002-01-01 Treatments

    A wide range of evidence shows that cholinesterase (ChE) inhibitors can interfere with the progression of Alzheimer's disease (AD).

From across this topic

9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

Other topics